CELZ
Creative Medical Technology Holdings, Inc. (CELZ) SWOT Analysis Analysis (2026)
No material changes this month.
Strengths
The company’s current ratio of 12.9 and quick ratio of 12.7 indicate exceptional near-term liquidity versus peers, reducing refinancing pressure despite weak operating performance.
A net debt to EBITDA ratio of 1.43 suggests leverage is not yet extreme relative to distressed microcap peers, preserving some financial flexibility.
The reported cash conversion cycle of -3714 days implies unusually favorable working-capital timing, which can support liquidity more effectively than peers with positive cycles.
Weaknesses
Return on invested capital of -71.9% shows capital is being destroyed at a severe rate, leaving CELZ structurally weaker than profitable peers on value creation.
The absence of reported operating and gross margins suggests the business is not demonstrating durable unit economics, unlike peers with visible margin support.
A debt-to-equity ratio of zero does not offset the weak earnings base, because balance-sheet simplicity cannot compensate for persistent negative returns versus peers.
Opportunities
If management converts its strong liquidity into operating scale, CELZ could narrow the gap with peers that currently outperform on profitability and capital efficiency.
The very high current and quick ratios provide room to fund development or commercialization longer than more constrained peers, supporting execution optionality.
A negative cash conversion cycle can be leveraged to preserve cash during growth initiatives, which may matter more than peers with slower working-capital turns.
Threats
Persistent negative ROIC increases the risk that CELZ remains structurally uncompetitive versus peers that can compound capital at positive returns.
If liquidity is consumed by ongoing losses, the current balance-sheet cushion could erode quickly, leaving CELZ weaker than better-capitalized peers.
The lack of demonstrated margin durability leaves CELZ exposed to execution setbacks, while peers with established profitability can absorb shocks more effectively.
Overall Score
CELZ is structurally कमजोर versus peers because extreme negative returns on capital dominate the analysis, while liquidity only partially offsets weak operating economics.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Creative Medical Technology Holdings, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.
